FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, in particular to a method for predicting the breast cancer outcome in an estrogen-receptor-positive and HER2-negative tumor in a patient with breast cancer, which involves determining in the tumor sample of the patient the expression level of RNA genes UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST and MGP or genes UBE2C, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST and MGP, mathematical combination of values of expression levels, where a higher composite indicator indicates a worse prognosis for said patient compared to a lower composite indicator.
EFFECT: invention allows to effectively predict the breast cancer outcome.
10 cl, 3 dwg, 10 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING RISK OF BREAST CANCER PROGRESSION WITH UNDERLYING TAMOXIFEN TAKING INTO ACCOUNT EXPRESSION CHARACTERISTICS OF TUMOUR | 2023 |
|
RU2823488C1 |
| METHOD FOR DIAGNOSING BREAST CANCER BY LEVEL OF MRNA TGEβ AND TNFα IN BLOOD PLASMA | 2019 |
|
RU2742209C1 |
| METHOD FOR DIAGNOSING BREAST CANCER AND OVARIAN CANCER BY MMP-9 MRNA LEVEL IN BLOOD PLASMA | 2020 |
|
RU2745424C1 |
| METHODS AND KITS FOR MOLECULAR SUBTYPING OF TUMORS | 2014 |
|
RU2690241C2 |
| DIAGNOSTIC METHOD OF RENAL CELL CARCINONMA | 2016 |
|
RU2643586C1 |
| METHOD FOR PREDICTING EARLY RECURRENCE OF CLEAR CELL CARCINOMA OF THE UTERINE BODY | 2022 |
|
RU2784775C1 |
| TEST-SYSTEM FOR PREDICTION OF RELAPSE DEVELOPMENT IN PATIENTS WITH UTERINE CORPUS CANCER BASED ON EXPRESSION LEVEL OF THE ESR1 GENE | 2017 |
|
RU2661599C1 |
| METHOD OF PERSONALIZATION OF MEDICAL CARE FOR PATIENTS WITH STOMACH CANCER | 2019 |
|
RU2713907C1 |
| METHOD OF ESTIMATING EFFICIENCY OF THERAPY URINARY BLADDER CANCER IN HUMANS BY METHOD OF IMMUNOFERMENTATIVE ANALYSIS | 2011 |
|
RU2468088C1 |
| METHOD OF DETERMINING PROBABILITY OF RECURRENT BREAST CANCER | 2014 |
|
RU2609199C2 |
